Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyGastroenterologic OncologyDiseaseNeuroendocrine CarcinomaPancreatic CancerSubgroupICD10C25.-C80.9MeSHCarcinoma, NeuroendocrinePancreatic NeoplasmsSequenceChemotherapyChemo-substanceCapecitabineCisplatinEtoposideFluorouracilFolinic acidIrinotecanTemozolomideChemo-substanceCapecitabineCisplatinEtoposideFluorouracilFolinic acidIrinotecanTemozolomideChemo-substanceCapecitabineCisplatinEtoposideFluorouracilFolinic acidIrinotecanTemozolomideChemo-substanceCapecitabineCisplatinEtoposideFluorouracilFolinic acidIrinotecanTemozolomideNo. Substances23 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFilgrastimFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFilgrastimFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFilgrastimFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFilgrastimFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideNo. Substances37Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlAnemia Hb below 10g/dlAnorexiaCholangitisDiarrheaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHand-Foot SyndromeHypokalemiaHyponatremiaIncrease AminotransferasesNauseaNeutropeniaThrombocytopenia below 50 000/µl only studiesPublicationAuthorMorizane CStrosberg JRWalter TDiseaseNeuroendokrines Karzinom, gastroententeropankreatisch, nach Erstlinie mit Cisplatin, ECOG 0-2Neuroendokrines Karzinom des Verdauungstraktes, nicht resezierbar, Erstlinie, ECOG 0-1pankreatisches neuroendokrines Karzinom, ErstlinieOriginDepartment of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, FloridaDepartment of Medical Oncology, Hôpital Edouard Herriot, Hospices Civils de Lyon, France, RODIGE 41-BEVANECJapan Clinical Oncology Group (JCOG), TOPIC-NETProtocols in Revision 4 protocols foundProtocols under revision.Capecitabine 750 / Temozolomide 200, pancreatic neuroendocrine carcinoma (PID1313 V1.1)Cisplatin 60 / Irinotecan 60, gastroenteral and pancreatic neuroendocrine carcinoma (PID2180 V1.0)Cisplatin 80 / Etoposide 100, gastroenteral and pancreatic neuroendocrine carcinoma (PID2174 V1.0)FOLFIRI - Irinotecan 180 / Folinic Acid 400 / Fluorouracil 2400, gastroenteric and pancreatic neuroendocrine Cancer (PID2631 V1.0)
